November 14, 2005 12:30 ET

Nymox Reports Third Quarter 2005 Financial Results

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Nov 14, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2005. Product sales increased by 31% for the first nine months of 2005 compared to the same period in 2004. Product sales for the first nine months of 2005 amounted to $318,424, compared to $243,579 for the same period in 2004. Nymox reported a net loss of $958,464, or $0.04 per share, for the quarter compared to $695,031, or $0.03 per share, for the same period in 2004, and $2,763,440, or $0.11 per share, for the nine months ended September 30, 2005, compared to $2,801,353, or $0.11 per share, for the nine months ended September 30, 2004. Nymox currently has $13 million in financing available from its most recent October 21, 2005 financing. The weighted, diluted average number of common shares at September 30, 2005 was 25,936,032, compared to 25,013,214 at September 30, 2004.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure, and AlzheimAlert™, a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    Web site: www.nymox.com